If you do not have easy access to Fibroscan, what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk stratify them?   

Great question. I do MRE, and if not possible, SWE. If I have access to only blood-based NILDA, will then order ELF. However, for CSPH specifically, you need to prioritize imaging-based NILDA which are more accurate and have been further studied.